title: Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study.
abstract: Treatment with statins to achieve target low-density lipoprotein cholesterol (LDL-C) levels is still associated with residual risk. Lipoprotein subfraction evaluation can provide additional information regarding atherogenicity in these individuals. Patients (n = 40) with hypercholesterolemia (29 females, mean age 63 years), without previous hypolipemic treatment, were treated with atorvastatin 40 mg/d for 3 months. Atorvastatin significantly reduced total cholesterol (6.7 ± 1.0 vs 4.6 ± 1.3 mmol/L, P < .001), LDL-C (4.3 ± 1.0 vs 2.6 ± 0.9 mmol/L, P < .001), triglycerides (1.8 ± 0.9 vs 1.5 ± 1.00 mmol/L, P < .05), small-dense LDL (sdLDL) fraction 3 to 7 (0.22 ± 0.37 vs 0.09 ± 0.16 mmol/L, P < .001), and apolipoprotein B (apoB; 1.0 ± 0.2 vs 0.74 ± 0.2 g/L, P < .001). There was a negative correlation of atherogenic index of plasma (AIP) with buoyant LDL-1 and LDL-2 (r = -.35; P < .05) and positive with sdLDL-3 to sdLDL-7 (r = .52, P < .001). Administration of atorvastatin 40 mg/d in patients with hypercholesterolemia caused a shift in sdLDL subfractions to large, buoyant subfractions. The AIP better correlated with sdLDL than apoB levels.
authors.affiliation: 2nd Medical Clinic, Faculty of Medicine, Comenius University Bratislava, Bratislava, Slovakia marekucera@gmail.com.
authors.forename: Marek
authors.initials: M
authors.lastname: Kucera
authors.affiliation: 2nd Medical Clinic, Faculty of Medicine, Comenius University Bratislava, Bratislava, Slovakia.
authors.forename: Stanislav
authors.initials: S
authors.lastname: Oravec
authors.affiliation: 2nd Medical Clinic, Faculty of Medicine, Comenius University Bratislava, Bratislava, Slovakia.
authors.forename: Eva
authors.initials: E
authors.lastname: Hirnerova
authors.affiliation: 2nd Medical Clinic, Faculty of Medicine, Comenius University Bratislava, Bratislava, Slovakia.
authors.forename: Nada
authors.initials: N
authors.lastname: Huckova
authors.affiliation: 2nd Medical Clinic, Faculty of Medicine, Comenius University Bratislava, Bratislava, Slovakia.
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Celecova
authors.affiliation: 2nd Medical Clinic, Faculty of Medicine, Comenius University Bratislava, Bratislava, Slovakia.
authors.forename: Ludovit
authors.initials: L
authors.lastname: Gaspar
authors.affiliation: Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Lodz, Poland.
authors.forename: Maciej
authors.initials: M
authors.lastname: Banach
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001055:Apolipoproteins B / Q000097:blood; D050197:Atherosclerosis / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D000069059:Atorvastatin; D015415:Biomarkers / Q000097:blood; D002784:Cholesterol / Q000097:blood; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006951:Hyperlipoproteinemias / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011758:Pyrroles / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D001055:Apolipoproteins B; D015415:Biomarkers; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL; D011758:Pyrroles; D014280:Triglycerides; D002784:Cholesterol; D000069059:Atorvastatin
keywords: apolipoprotein B; atherogenic dyslipidemia; atherogenic index of plasma; atorvastatin; cardiovascular risk; small-dense LDL